More Than 100 Patient Groups Warn Against Eliminating Protected Drug Classes In Part D

More than 100 patient-advocate groups are warning against eliminating coverage protections for drugs in six therapeutic classes in an upcoming Part D proposed rule. The contents of the proposal are unknown, but lobbyists for industry and patients are on edge because CMS plans to propose the first Part D rule since it pursued aggressive policy changes three years ago, according to the regulatory agenda. Part D plans currently must cover all drugs in six therapeutic classes: anti-retrovirals; immunosuppressants when used...